Vishal Sikri

Vishal Sikri has over 24 years of Oncology and Infectious Disease diagnostics experience in both the global IVD and LDT settings. His last 15 years has been focused primarily in Oncology especially in solid tumor tissue and liquid biopsies across multiple testing modalities. He previously was the commercial officer at Sysmex Inostics, a liquid biopsy ctDNA company. From there, he moved to Biocartis US, where he was the General Manager, responsible for all commercial and operational activities, selling instruments and solid tumor Oncology tests to hospitals and testing labs in the US. He then moved to Invitae where the team launched the company’s first MRD (Minimal Residual Disease) tests clinically. Vishal recently served as the President of Advanced Diagnostics at NeoGenomics, a large community focused reference lab company. Vishal joined the ETG team in January of 2025.

President, Eurofins Transplant Genomics, LLC

Neal Beswick

Neal joined Transplant Genomics in August 2020 and is the VP of commercial operations. Neal has worked in the commercial transplant field for over 15 years focused on advanced preservation systems for all solid organs and molecular biomarkers for the kidney and liver during his 4 year tenure at Transplant Genomics. The transplant field and more specifically the pursuit of improving patient outcomes post-transplant is a passion for Neal where knowledge and imagination can fuel much needed innovation in guiding monitoring and therapy titration.

Vice President of Commercialization

James Fleming, PharmD, FCCP, FAST

Dr. Fleming joined Transplant Genomics in November 2021 and is the Director of Medical Affairs and Clinical Trials. Dr. Fleming is transplant pharmacist with 11 years of clinical and academic experience
in both abdominal and cardiothoracic transplant and 5 years of biotechnology industry experience in medical affairs and clinical trials. He has authored over 100 scientific abstracts and over 50 peer-reviewed manuscripts that have appeared in numerous journals, including the American Journal of Transplantation. He has served as affiliate faculty for the Colleges of Pharmacy and Medicine at the Medical University of South Carolina.
Dr. Fleming earned his PharmD at the University of Iowa College of Pharmacy and completed his residency and solid organ transplant specialty residencies at UMass
Memorial Medical Center and the Medical University of South Carolina, respectively. He is currently completing his MPH at the Medical University of South Carolina College of Medicine, pending completion in December 2024.

Director of Medical Affairs and Clinical Trials

Steve Kleiboeker, DVM, PhD

Steve Kleiboeker, DVM, PhD, Vice President of Research and Development, is responsible for the scientific direction and oversight of the Company’s research and development programs. Dr. Kleiboeker’s research focuses on diagnostic virology, immunology and infectious diseases as well as transplant monitoring. He is board certified as a high-complexity laboratory director, technical supervisor and clinical consultant by the American Board of Bioanalysis. Dr. Kleiboeker received his PhD and DVM from the University of Missouri.

Vice President of Research and Development & Lab Director

Leadership